A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

• Main Authors: Chen, Yunxin, Gopalakrishnan, Sathish Kumar, Ooi, Melissa, Sultana, Rehena, Lim, Li Hui, Grigoropoulos, Nicholas, Ong, Shin Yeu, Xu, Mingge, Chng, Wee Joo, Goh, Yeow Tee, Nagarajan, Chandramouli
• 其他作者: MEDICINE
• 格式: Letter
• 語言: English
• 出版: SPRINGERNATURE 2021
• 主題: Science & Technology; Life Sciences & Biomedicine; Oncology; Hematology; MULTIPLE-MYELOMA; LENALIDOMIDE
• 在線閱讀: https://scholarbank.nus.edu.sg/handle/10635/207736

10.1038/s41408-021-00544-x